Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Adrenoceptor alpha 1A |
| Gene Name | ADRA1A |
| Uniprot | P35348 (Human); P97718 (Mouse) |
| Synonym | ADRA1C; ADRA1L1; ALPHA1AAR; G protein coupled receptor; alpha-1A adrenoceptor; alpha-1A adrenoreceptor; alpha-1C adrenergic receptor |
| Background | Alpha-1-adrenergic receptor (ADRA1A), which is encoded by the ADRA1A gene, is a member of the G protein-coupled receptor superfamily. The translation of ADRA1A is regulated by alpha-1 adrenergic receptors and Monoamine GPCRs. It is associated with a number of diseases including Horner's Syndrome and Ureter cancer. Gene Ontology annotations related to ADRA1A include alpha1-adrenergic receptor activity and G-protein coupled receptor activity. Alpha-1-adrenergic receptors activate mitogenic responses and regulate growth and proliferation of many cells. 3 alpha-1-AR subtypes are alpha1A, alpha1B, and alpha1D receptors. All subtypes signal through the Gq/11 family of G-proteins but show different patterns of activation. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX330 | NativeExtract™ Human ADRA1A Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MPX3594K | MemDX™ Membrane Protein Human ADRA1A Expressed in vitro E.coli expression system, Full Length | E.coli cell-free | Full length | Detergent |
| Please for more products or customization | ||||
C**e: High-purity ADRA1A for precision assays.
03/May/2023
J***n: Seamless custom ADRA1A services. Ideal for GPCR signaling studies.
27/Jan/2024
ADRA1A Gene Therapy Development
We provide tailored solutions to meet your specific requirements. Please for more services.
Allelic Correction for ADRA1A Dysregulation
Creative Biolabs offers allelic correction services for ADRA1A dysregulation. Advances in genome editing enable precise correction of ADRA1A mutations implicated in hypertensive disorders. By targeting single-nucleotide polymorphisms within the ADRA1A promoter region, researchers can restore normal receptor expression in vascular smooth muscle cells, potentially mitigating pathological vasoconstriction. Creative Biolabs' proprietary RNA design platform ensures high specificity for such applications, minimizing off-target effects while maximizing therapeutic efficacy.
AAV-Delivered ADRA1A Overexpression for Autonomic Dysfunction
Creative Biolabs offers AAV-delivered ADRA1A overexpression services for autonomic dysfunction. Recombinant adeno-associated virus (AAV) vectors engineered with tissue-specific promoters (e.g., SYN1 for neuronal targeting) can deliver functional ADRA1A copies to adrenergic synapses. Preclinical studies demonstrate that AAV9-mediated ADRA1A overexpression in the locus coeruleus reduces sympathetic hyperactivity, offering promise for disorders like neurogenic hypertension. Creative Biolabs' AAV serotype optimization services ensure robust transduction efficiency across diverse biological systems.
siRNA-Based ADRA1A Silencing in Hyperadrenergic States
Creative Biolabs offers siRNA-based ADRA1A silencing services. Lipid nanoparticle-encapsulated siRNAs targeting ADRA1A mRNA effectively suppress receptor overactivity in preclinical models of pheochromocytoma. This strategy leverages sequence-specific RNA interference to downregulate ADRA1A in adrenal medullary cells, normalizing catecholamine secretion. Creative Biolabs' end-to-end siRNA synthesis and delivery platforms streamline therapeutic development for such oncological applications.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADRA1A cell therapy. Please for more services.
ADRA1A-Engineered CAR-T Cells for Neuroendocrine Tumors
Creative Biolabs offers ADRA1A-engineered CAR-T cell development services. Chimeric antigen receptor (CAR) T cells engineered to recognize ADRA1A-positive neuroendocrine tumor cells exhibit potent cytotoxicity in vitro. By incorporating ADRA1A extracellular domain-specific scFv fragments, these CAR-T constructs enable targeted elimination of malignant cells while sparing healthy tissues. Creative Biolabs' lentiviral vector development services support scalable production of such next-generation immunotherapies.
iPSC-Derived Adrenergic Neurons with Modulated ADRA1A Activity
Creative Biolabs offers iPSC-derived adrenergic neurons development services. Induced pluripotent stem cells (iPSCs) differentiated into adrenergic neurons can be epigenetically edited to overexpress or silence ADRA1A, creating patient-specific models for autonomic neuropathy. These cells enable high-throughput screening of ADRA1A-targeted compounds, accelerating therapeutic discovery. Creative Biolabs' genome editing kits facilitate seamless integration of such modifications.
Lentiviral ADRA1A Knockdown in Sympathetic Ganglia
Creative Biolabs offers lentiviral ADRA1A knockdown services in sympathetic ganglia. Lentiviral vectors encoding shRNAs against ADRA1A achieve sustained receptor suppression in sympathetic ganglia, attenuating norepinephrine-driven pathologies like arrhythmogenic cardiomyopathy. Creative Biolabs' custom shRNA design services ensure optimal silencing efficiency and minimal interferon response, critical for translational success.
Leverage our expertise in gene editing design, viral vector engineering, and cell therapy development to advance your ADRA1A-focused programs. Please feel free to to explore tailored solutions that align with your therapeutic objectives.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
